165 related articles for article (PubMed ID: 38787503)
41. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
42. Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.
Yoon N; Park MS; Shigemoto T; Peltier G; Lee RH
Cell Death Dis; 2016 Apr; 7(4):e2191. PubMed ID: 27077807
[TBL] [Abstract][Full Text] [Related]
43. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
44. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
45. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels.
Kisim A; Atmaca H; Cakar B; Karabulut B; Sezgin C; Uzunoglu S; Uslu R; Karaca B
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1155-63. PubMed ID: 22411600
[TBL] [Abstract][Full Text] [Related]
46. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.
Oh B; Park S; Pak JH; Kim I
Biochem Biophys Res Commun; 2012 May; 422(1):42-7. PubMed ID: 22554523
[TBL] [Abstract][Full Text] [Related]
47. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
48. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
[TBL] [Abstract][Full Text] [Related]
49. Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.
Gottwald L; Piekarski J; Kubiak R; Szwalski J; Pasz-Walczak G; Sęk P; Spych M; Suzin J; Tyliński W; Jeziorski A
Arch Gynecol Obstet; 2013 Oct; 288(4):889-99. PubMed ID: 23584885
[TBL] [Abstract][Full Text] [Related]
50. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
[TBL] [Abstract][Full Text] [Related]
51. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
[TBL] [Abstract][Full Text] [Related]
52. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
[TBL] [Abstract][Full Text] [Related]
53. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
54. Epithelial-specific ETS-1 (ESE1/ELF3) regulates apoptosis of intestinal epithelial cells in ulcerative colitis via accelerating NF-κB activation.
Li L; Miao X; Ni R; Miao X; Wang L; Gu X; Yan L; Tang Q; Zhang D
Immunol Res; 2015 Jun; 62(2):198-212. PubMed ID: 25926267
[TBL] [Abstract][Full Text] [Related]
55. Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
Reinhardt A; Liu H; Ma Y; Zhou Y; Zang C; Habbel JP; Possinger K; Eucker J
Anticancer Res; 2018 May; 38(5):2669-2682. PubMed ID: 29715087
[TBL] [Abstract][Full Text] [Related]
56. Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.
Xu Y; Li J; Li QJ; Feng YL; Pan F
Biomed Pharmacother; 2017 Apr; 88():349-358. PubMed ID: 28119237
[TBL] [Abstract][Full Text] [Related]
57. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kazhdan I; Marciniak RA
Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
[TBL] [Abstract][Full Text] [Related]
58. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
59. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
[TBL] [Abstract][Full Text] [Related]
60. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
